A scientist from the University of Massachusetts Medical School recently found a way to improve photodynamic therapy, which basically makes use of specific light molecules to target cancer tumors. This is a relatively new discovery in the medical industry, but it is fast getting traction thanks to the multitude of potential applications.
Gang Han, Ph.D. is the one who designed the new way to take advantage of photodynamic therapy to improve upon it along with his team, Phys.org reports. Trained in biochemistry & molecular pharmacology, Han is an associate professor at the university.
He and his team explained how the carbazole-substituted BODIPY (Car-BDP) can vastly improve the results of photodynamic therapy thanks to its NIR absorption band. Since its singlet oxygen quantum yield is exceedingly high, it leads to some unique results.
"This study signals a major step forward in photodynamic therapy by developing a new class of NIR-absorbing biodegradable organic nanoparticles for a highly effective targeting and treatment of deep-tissue tumors," Han said.
The results of the study were posted on the Journal of the American Chemical Society, where Han explains that after using the PLA–PEG-FA, which is a highly biodegradable polymer to encapsulate Car-BDP, the compound formed nanoparticles that possessed small, uniformed, organic, and water-soluble properties and is able to target tumors.
This helps overcome one of the bigger challenges that stop the wider adoption of photodynamic therapy, which is how shallow the penetration to tissue is right now. Normally, this is addressed via the introduction of drugs that are non-toxic and sensitive to light. Once the drug is inside the body, a laser is tuned with the molecules of the substances in the drug, which then targets the tumor.
Han and his team are proposing to make the whole thing simpler using Car-BDP and pairing it with a lamp light that has low power density. The molecules released by this method can be tracked as well, which makes monitoring which tumors have been targeted much easier.


Arm Stock Drops Despite Strong AI Chip Demand and Earnings Beat
Japan Tech Stocks Surge as AI Optimism Lifts SoftBank, Chipmakers
Vanda Pharmaceuticals (VNDA) Stock Soars After FDA Approves BYSANTI for Bipolar I and Schizophrenia
Intermittent fasting doesn’t have an edge for weight loss, but might still work for some
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Why the future of marijuana legalization remains hazy despite high public support
Broadcom Eyes $35 Billion AI Chip Financing Deal With Apollo and Blackstone
Novo Nordisk Shares Tumble After CagriSema Misses Key Trial Endpoint
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance
CoreWeave Q1 2026 Revenue Surges as AI Infrastructure Demand Grows
Ibiden Stock Surges as AI Chip Demand Boosts Profit Outlook
GOP Lawmakers Probe Sam Altman and OpenAI Ahead of Potential IPO
Trump Reportedly Approves Plan to Remove FDA Commissioner Marty Makary Amid Growing Controversies 



